Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Boceprevir for previously treated chronic HCV genotype 1 infection.

The New England journal of medicine - 31 Mar 2011

Bacon Bruce R, Gordon Stuart C, Lawitz Eric, Marcellin Patrick, Vierling John M, Zeuzem Stefan, Poordad Fred, Goodman Zachary D, Sings Heather L, Boparai Navdeep, Burroughs Margaret, Brass Clifford A, Albrecht Janice K, Esteban Rafael

Abstract excerpt

BACKGROUND: In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment. METHODS: To assess the effect of the combination of boceprevir and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Proline

Share to Retreatment

Share to Ribavirin

Share to Serine Proteinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 21449784
DOI: 10.1056/NEJMoa1009482
PMCID: PMC3153125

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Boceprevir for previously treated chronic HCV genotype 1 infection.PMID 21449784Read ↗

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Boceprevir for untreated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionSemantic proximity Read ↗

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Boceprevir for Chronic HCV Genotype 1 InfectionSemantic proximity Read ↗

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.Semantic proximity Read ↗

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Semantic proximity Read ↗

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.Semantic proximity Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Semantic proximity Read ↗

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.